ADMA Biologics vs Cytokinetics
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put ADMA Biologics and Cytokinetics side by side, using each oneβs latest annual report. Here is what stands out:
- ADMA Biologics is the larger business, with $510M of revenue in fiscal 2025 against $88.0M for Cytokinetics, about 5.8 times as much.
- Cytokinetics grew revenue faster (376.6%, against 19.6%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against β695.4%).
- ADMA Biologics turned more of its sales into free cash flow (5.5% FCF margin, against β607.5%).
Who comes out ahead
Of the 5 measures where higher (or lower) is clearly better, how many each company leads.
ADMA Biologics
ADMA
4/5
5-year growthOperating marginNet marginFCF margin
Cytokinetics
CYTK
1/5
Revenue growth
Side by side
Best in the row
| Latest fiscal year | ADMA FY25 | CYTK FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | β |
| Revenue | $510M | $88.0M |
| Free cash flow | $27.8M | β$535M |
| Net income | $147M | β$785M |
| Growth | ||
| Revenue growth | 19.6% | 376.6% |
| 5-year growth | 64.6% | 9.5% |
| Share count change | 0.6% | β |
| Profitability | ||
| Gross margin | 57.4% | β |
| Operating margin | 37.5% | β695.4% |
| Net margin | 28.8% | β891.6% |
| FCF margin | 5.5% | β607.5% |
| Return on capital | 39.5% | β |
| Return on equity | 35.6% | β |
| Balance sheet | ||
| Net debt | β$15.5M | β$912M |
| Net debt / EBITDA | β0.1x | β |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | β |
| Piotroski F-score | 5 | β |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.